Table 2.

Selected randomized studies of bevacizumab in first-line metastatic colorectal cancer

Studies	Phase	Chemotherapy regimen	n	Time to progression (months)	Response rate (%)	Median survival (months)
Hurwitz9	III	IFL + BV 5 mg/kg	402	10.6	44.8	20.3
BICC-C8	III	FOLFIRI + BV 5 mg/kg	57	11.2	57.9	28
		mIFL + BV 5 mg/kg	60	8.3	53.3	19.2
AVIRI52	IV	FOLFIRI + BV 5 mg/kg	209	11.1	44	NRa
TREE-254	II	FOLFOX + BV 5 mg/kg	71	9.9	52	26.1
		bFOL + BV 5 mg/kg	70	8.3	39	20.4
		CapeOX + BV 5 mg/kg	72	10.3	46	24.6
N1696655	III	FOLFOX or XELOX + BV 5 mg/kg	699	9.4	49	21.3

^aNR, not reported.